PRAX Quote, Financials, Valuation and Earnings

IGC Pharma has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -711.67%. Praxis Precision Medicines's return on equity of -59.11% beat IGC Pharma's return on equity of -116.24%.

Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 120.47%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1191.67%. Given that IGC Pharma has higher upside potential than Praxis Precision Medicines, analysts believe IGC Pharma is more attractive than Praxis Precision Medicines.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.479, suggesting its more volatile than the S&P 500 by 47.852%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $7.5M, which are larger than IGC Pharma quarterly revenues of $257K. Praxis Precision Medicines's net income of -$69.3M is lower than IGC Pharma's net income of -$1.8M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 101.98x versus 17.64x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Lineage Cell Therapeutics has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -275.57%. Praxis Precision Medicines's return on equity of -59.11% beat Lineage Cell Therapeutics's return on equity of -22.68%.

Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 120.47%. On the other hand Lineage Cell Therapeutics has an analysts' consensus of $3.92 which suggests that it could grow by 383.24%. Given that Lineage Cell Therapeutics has higher upside potential than Praxis Precision Medicines, analysts believe Lineage Cell Therapeutics is more attractive than Praxis Precision Medicines.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Lineage Cell Therapeutics has a beta of 1.517, suggesting its more volatile than the S&P 500 by 51.713%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lineage Cell Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. Lineage Cell Therapeutics pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $7.5M, which are larger than Lineage Cell Therapeutics quarterly revenues of $1.5M. Praxis Precision Medicines's net income of -$69.3M is lower than Lineage Cell Therapeutics's net income of -$4.1M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while Lineage Cell Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 101.98x versus 17.89x for Lineage Cell Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -49.65%. Praxis Precision Medicines's return on equity of -59.11% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 120.47%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 41.67%. Given that Praxis Precision Medicines has higher upside potential than NovaBay Pharmaceuticals, analysts believe Praxis Precision Medicines is more attractive than NovaBay Pharmaceuticals.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $7.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Praxis Precision Medicines's net income of -$69.3M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 101.98x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -35.79%. Praxis Precision Medicines's return on equity of -59.11% beat Protalix BioTherapeutics's return on equity of 10.9%.

Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 120.47%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 839.6%. Given that Protalix BioTherapeutics has higher upside potential than Praxis Precision Medicines, analysts believe Protalix BioTherapeutics is more attractive than Praxis Precision Medicines.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.210, suggesting its less volatile than the S&P 500 by 120.951%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $7.5M, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. Praxis Precision Medicines's net income of -$69.3M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 37.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 101.98x versus 2.09x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.